Nothing Special   »   [go: up one dir, main page]

MX2011008197A - Compuestos de fenilimidazol. - Google Patents

Compuestos de fenilimidazol.

Info

Publication number
MX2011008197A
MX2011008197A MX2011008197A MX2011008197A MX2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A MX 2011008197 A MX2011008197 A MX 2011008197A
Authority
MX
Mexico
Prior art keywords
hydrogen atom
lower alkyl
group
alkyl group
lower alkoxy
Prior art date
Application number
MX2011008197A
Other languages
English (en)
Inventor
Koushi Iwata
Tadao Shibutani
Satoshi Kido
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2011008197A publication Critical patent/MX2011008197A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se provee un producto farmacéutico (agente quimioterapéutico) efectivo en la prevención y tratamiento de hiperlipidemia, obesidad, etc.; un compuesto de fenilimidazol representado por la siguiente fórmula general (1):(ver fórmula (I)) en donde, R1 representa un átomo de hidrógeno, un grupo fenil-alquilo inferior que tiene opcionalmente un sustituyente, o un grupo piridil-alquilo inferior que iene opcionalmente un sustituyente, y el anillo de benceno y el anillo de piridina son opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados del grupo que consiste de átomos de halógeno, grupo ciano y grupos alquilo inferior halógeno-sustituidos; uno de R2 y R3 representa un átomo de hidrógeno y el otro representa un grupo alquilo inferior; R4 representa un grupo fenilo que tiene opcionalmente un sustituyente; R5 y R6 son los mismos o diferentes, y representan un átomo de hidrógeno o un grupo alquilo inferior; R7 y R8 son los mismos o diferentes, y representan un átomo de hidrógeno o un grupo alquilo inferior; sin embargo, cuando R1 representa un grupo fenil alquilo inferior no sustituido, R2 representa un grupo alquilo inferior, R3 representa un átomo de hidrógeno, R4 representa un grupo fenilo que tiene opcionalmente un sustituyente, y R5 representa un átomo de hidrógeno, R6 no es un átomo de hidrógeno.
MX2011008197A 2009-02-04 2010-02-03 Compuestos de fenilimidazol. MX2011008197A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009023793 2009-02-04
JP2009255980 2009-11-09
PCT/JP2010/051469 WO2010090200A1 (ja) 2009-02-04 2010-02-03 フェニルイミダゾール化合物

Publications (1)

Publication Number Publication Date
MX2011008197A true MX2011008197A (es) 2011-08-17

Family

ID=42542093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008197A MX2011008197A (es) 2009-02-04 2010-02-03 Compuestos de fenilimidazol.

Country Status (22)

Country Link
US (1) US8329739B2 (es)
EP (1) EP2394996B8 (es)
JP (1) JP5540227B2 (es)
KR (1) KR101676889B1 (es)
CN (1) CN102307861B (es)
AR (1) AR075245A1 (es)
AU (1) AU2010211753B2 (es)
BR (1) BRPI1007902B1 (es)
CA (1) CA2750704C (es)
DK (1) DK2394996T3 (es)
ES (1) ES2587942T3 (es)
HK (1) HK1160123A1 (es)
HU (1) HUE028840T2 (es)
MX (1) MX2011008197A (es)
MY (1) MY156539A (es)
PL (1) PL2394996T3 (es)
PT (1) PT2394996T (es)
RU (1) RU2497811C2 (es)
SG (1) SG172895A1 (es)
TW (1) TWI435871B (es)
WO (1) WO2010090200A1 (es)
ZA (1) ZA201104932B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5398743B2 (ja) 2008-05-14 2014-01-29 株式会社大塚製薬工場 ベンゼン誘導体を含むリポプロテインリパーゼ活性化組成物
US8957216B2 (en) 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
SG11201705013QA (en) 2014-12-19 2017-07-28 Galderma Res & Dev Novel compounds, synthesis method thereof and use of same in medicine and in cosmetics
EP3401310B1 (en) * 2015-12-25 2022-04-06 Otsuka Pharmaceutical Factory, Inc. Phenylimidazole compound
CN106946862B (zh) * 2017-03-31 2019-09-03 枣庄学院 1-烷烃-6-甲基-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法
KR20230044481A (ko) * 2020-07-30 2023-04-04 가부시키가이샤 오츠까 세이야꾸 고죠 감기약 및 항바이러스제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI57407C (fi) * 1971-05-11 1980-08-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av nya farmakologiskt verksamma i 2-staellningen substituerade 4(5)-pyridyl-5(4)-fenyl-imidazoler
DE3411997A1 (de) * 1984-03-31 1985-10-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue redox-indikatoren
JP2001226358A (ja) * 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
WO2008153957A1 (en) 2007-06-07 2008-12-18 The Trustees Of Columbia University In The City Of New York Uses of rage antagonists for treating obesity and related diseases
JP5398743B2 (ja) * 2008-05-14 2014-01-29 株式会社大塚製薬工場 ベンゼン誘導体を含むリポプロテインリパーゼ活性化組成物

Also Published As

Publication number Publication date
CA2750704C (en) 2016-11-22
AU2010211753B2 (en) 2015-11-05
RU2011136719A (ru) 2013-03-10
DK2394996T3 (en) 2016-08-01
EP2394996A1 (en) 2011-12-14
HUE028840T2 (en) 2017-01-30
JPWO2010090200A1 (ja) 2012-08-09
EP2394996A4 (en) 2012-09-12
BRPI1007902B1 (pt) 2022-01-04
ZA201104932B (en) 2012-09-26
US8329739B2 (en) 2012-12-11
PT2394996T (pt) 2016-08-31
WO2010090200A1 (ja) 2010-08-12
TWI435871B (zh) 2014-05-01
TW201033179A (en) 2010-09-16
KR20110111300A (ko) 2011-10-10
CA2750704A1 (en) 2010-08-12
PL2394996T3 (pl) 2016-12-30
KR101676889B1 (ko) 2016-11-16
CN102307861A (zh) 2012-01-04
ES2587942T3 (es) 2016-10-27
AU2010211753A1 (en) 2011-07-28
RU2497811C2 (ru) 2013-11-10
HK1160123A1 (zh) 2012-08-10
SG172895A1 (en) 2011-08-29
BRPI1007902A2 (pt) 2020-08-18
AR075245A1 (es) 2011-03-16
MY156539A (en) 2016-02-26
US20110275823A1 (en) 2011-11-10
EP2394996B1 (en) 2016-06-22
CN102307861B (zh) 2014-10-29
JP5540227B2 (ja) 2014-07-02
EP2394996B8 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
MX2010009736A (es) Compuesto heterociclico.
UA104017C2 (en) Pyridazinone compound and use thereof
MY196864A (en) Piperazine-substituted benzothiophene derivatives as antipsychotic agents
MX2011008197A (es) Compuestos de fenilimidazol.
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
MX2009012345A (es) Derivados de 3,3-espiroindolinona.
TN2010000148A1 (en) Amide compound
MX2009010846A (es) Proceso para producir compuesto pesticidas de benzamidas.
HRP20130653T1 (en) Pyrrole compounds
TW200730486A (en) Organic sulfur compounds and use thereof
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX343625B (es) Composiciones plagicidas.
GEP20146079B (en) Microbiocidal heterocycles
MX2011006373A (es) Compuestos de carbodiimida ciclica.
MX2009010814A (es) Compuestos de hidrazida y agente controlador de artropodos dañinos que contiene el mismo.
MX2009013730A (es) Compuesto amina y uso farmaceutico del mismo.
TW200722433A (en) Phosphorus compounds, use thereof and flame retarding polyester fibers
MX2014001023A (es) Derivados de quinazolina.
PH12012502033A1 (en) Pesticidal composition and its use
GB201305247D0 (en) Amide Compounds
PH12012500762A1 (en) Benzazepine compound
MY155342A (en) Antitumoral compounds
TW200609224A (en) Organic compounds
MY169359A (en) Epoxy resin composition and electronic component device

Legal Events

Date Code Title Description
FG Grant or registration